That is a great question, I think it is dependent on a number of variables.
- Hype – often this is dictated by investors and popularity.
- Forecasted growth – This will grow in the next 12 months
- Maturity / potential of the company – This will grow in the next 12 months
I do believe that ALC has a significant re-rate in store. However, there needs to be a realisation from new investors of who/what we do at the end of the day.
A realisation is also needed on the whole Health IT sector imo.
price to sales ratio, page-2
Add ALC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
-0.002(2.97%) |
Mkt cap ! $65.78M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.1¢ | 4.8¢ | $22.09K | 444.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 480544 | 4.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 14098 | 1 |
View Market Depth
| Last trade - 15.56pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
4.9¢ |
Change
-0.002 ( 2.00 %) |
||||
| Open | High | Low | Volume | ||
| 5.1¢ | 5.1¢ | 4.7¢ | 330453 | ||
| Last updated 15.56pm 07/06/2024 ? | |||||
| ALC (ASX) Chart |